Wavelength-Pharmaceuticals-Insert
X

Find Oncology Drugs in Phase II Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taletrectinib

            Therapeutic Area: Oncology Product Name: AB-106

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            This Phase 2 trial will enroll approximately 106 NSCLC patients with ROS1 fusion and is designed as an open-label, single-arm, multi-center study in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taletrectinib

            Therapeutic Area: Oncology Product Name: AB-106

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NewG Lab

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 15, 2020

            Details:

            NewG Lab will be responsible for development, market authorization and commercialization activities for taletrectinib in Korea. AnHeart will allow NewG Lab to join its Phase 2 multi-regional clinical trial (MRCT) for non-small cell lung cancer (NSCLC) with ROS1/NTRK mutations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taletrectinib

            Therapeutic Area: Oncology Product Name: AB-106

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            Details:

            The lead clinical candidate taletrectinib is a next-generation novel, potent, highly selective ROS1 and NTRK inhibitor that can cross the blood-brain barrier.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HQP1351

            Therapeutic Area: Oncology Product Name: HQP1351

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            Guangzhou Healthquest Pharma has submitted a NDA to the Center for Drug Evaluation of China National Medical Products Administration for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia and accelerated phase CML.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Disitamab vedotin

            Therapeutic Area: Oncology Product Name: RC48

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            Results demonstrated a clinically meaningful response and survival benefit for heavily treated patients with unmet need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KN026,Docetaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 09, 2020

            Details:

            According to the terms of the agreement, after reaching certain clinical milestones, Sanofi will have the right to negotiate the exclusive right to introduce KN026 during the exclusive period.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JWCAR029

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: CR-CP Life Science Fund

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 09, 2020

            Details:

            JW Therapeutics plans to use the proceeds to further advance its lead product JWCAR029 (a CAR-T cell product targeting CD19 in clinical phase II), further build-out a pipeline, and gear up to establish commercialization capabilities to support product launch.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genolimzumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Hillhouse

            Deal Size: $160.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 02, 2020

            Details:

            Genor will use proceeds of the Series B round to finance the clinical development of its existing pipeline, R&D of early-stage innovative drugs, potential strategic partnerships at home and abroad, as well as preparation for the commercialisation of its mature products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efineptakin alfa

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            China National Medical Products Administration (NMPA) has cleared the initiation of a Phase 2 clinical trial of TJ107/HyLeukin-7™ (Efineptakin alfa), in lymphopenic patients with newly-diagnosed glioblastoma multiforme (GBM).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HQP1351

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            HQP1351 is the first 3rd generation BCR-ABL inhibitor developed in China targeting drug-resistant CML. A pivotal Phase II study is currently under way to test HQP1351. Ascentage plans to file an NDA.

            PharmaCompass